Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib and Nivolumab in Mycosis Fungoides and Sézary Syndrome
NCT04652960Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose or Recommended Phase II Dose at 3 months and Incidence of adverse events. Started Oct 2021; status: active, not recruiting.
02
Drugs
duvelisibnivolumab
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT04652960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652960.